Neurocrine Biosciences shares new data supporting Ingrezza's effectiveness in older adults with tardive dyskinesia. Read more ...

Neurocrine (NBIX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Wall Street expects flat earnings compared to the year-ago quarter on higher revenues when Neurocrine Biosciences (NBIX) reports results for the quarter ended March 2025. While this widely-known ...

Biosciences announced publication of a post-hoc analysis from two 48-week studies, the KINECT 3 extension and KINECT 4, ...

Evercore ISI analyst Cory Kasimov maintained a Buy rating on Neurocrine (NBIX – Research Report) yesterday and set a price target of $185.00.

(RTTNews) - Neurocrine Biosciences Inc. (NBIX) announced publication of a post-hoc analysis from two 48-week studies, the KINECT 3 extension and KINECT 4, demonstrating the long-term safety ...